Literature DB >> 7638170

Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins.

S Sanderson1, K Frauwirth, N Shastri.   

Abstract

CD4+ T cells recognize major histocompatibility complex (MHC) class II-bound peptides that are primarily obtained from extracellular sources. Endogenously synthesized proteins that readily enter the MHC class I presentation pathway are generally excluded from the MHC class II presentation pathway. We show here that endogenously synthesized ovalbumin or hen egg lysozyme can be efficiently presented as peptide-MHC class II complexes when they are expressed as fusion proteins with the invariant chain (Ii). Similar to the wild-type Ii, the Ii-antigen fusion proteins were associated intracellularly with MHC molecules. Most efficient expression of endogenous peptide-MHC complex was obtained with fusion proteins that contained the endosomal targeting signal within the N-terminal cytoplasmic Ii residues but did not require the luminal residues of Ii that are known to bind MHC molecules. These results suggest that signals within the Ii can allow endogenously synthesized proteins to efficiently enter the MHC class II presentation pathway. They also suggest a strategy for identifying unknown antigens presented by MHC class II molecules.

Mesh:

Substances:

Year:  1995        PMID: 7638170      PMCID: PMC41310          DOI: 10.1073/pnas.92.16.7217

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.

Authors:  R M Chicz; R G Urban; W S Lane; J C Gorga; L J Stern; D A Vignali; J L Strominger
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

2.  HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides.

Authors:  J M Riberdy; J R Newcomb; M J Surman; J A Barbosa; P Cresswell
Journal:  Nature       Date:  1992-12-03       Impact factor: 49.962

3.  Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant.

Authors:  A Sette; S Ceman; R T Kubo; K Sakaguchi; E Appella; D F Hunt; T A Davis; H Michel; J Shabanowitz; R Rudersdorf
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

4.  Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad.

Authors:  D F Hunt; H Michel; T A Dickinson; J Shabanowitz; A L Cox; K Sakaguchi; E Appella; H M Grey; A Sette
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

5.  Autoimmune diseases: the failure of self tolerance.

Authors:  A A Sinha; M T Lopez; H O McDevitt
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

6.  Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells.

Authors:  N Shastri; F Gonzalez
Journal:  J Immunol       Date:  1993-04-01       Impact factor: 5.422

7.  The segment of invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides.

Authors:  I M Freisewinkel; K Schenck; N Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

8.  Stable surface expression of invariant chain prevents peptide presentation by HLA-DR.

Authors:  P A Roche; C L Teletski; D R Karp; V Pinet; O Bakke; E O Long
Journal:  EMBO J       Date:  1992-08       Impact factor: 11.598

9.  Relationship between invariant chain expression and major histocompatibility complex class II transport into early and late endocytic compartments.

Authors:  P Romagnoli; C Layet; J Yewdell; O Bakke; R N Germain
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

10.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  V Brichard; A Van Pel; T Wölfel; C Wölfel; E De Plaen; B Lethé; P Coulie; T Boon
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

View more
  21 in total

1.  Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.

Authors:  K Frauwirth; N Shastri
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

2.  Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes.

Authors:  F Bischof; W Wienhold; C Wirblich; G Malcherek; O Zevering; A M Kruisbeek; A Melms
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

3.  DNA vaccine construct incorporating intercellular trafficking and intracellular targeting motifs effectively primes and induces memory B- and T-cell responses in outbred animals.

Authors:  Waithaka Mwangi; Wendy C Brown; Gary A Splitter; Christopher J Davies; Chris J Howard; Jayne C Hope; Yoko Aida; Yan Zhuang; Beverly J Hunter; Guy H Palmer
Journal:  Clin Vaccine Immunol       Date:  2007-01-10

4.  Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP.

Authors:  J van Bergen; S P Schoenberger; F Verreck; R Amons; R Offringa; F Koning
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

5.  Construction of the recombinant vaccine based on T-cell epitope encoding Der p1 and evaluation on its specific immunotherapy efficacy.

Authors:  Jinhong Zhao; Chaopin Li; Beibei Zhao; Pengfei Xu; Haifeng Xu; Lianping He
Journal:  Int J Clin Exp Med       Date:  2015-04-15

6.  Design of a ProDer f 1 vaccine delivered by the MHC class II pathway of antigen presentation and analysis of the effectiveness for specific immunotherapy.

Authors:  Zhiming Liu; Yuxin Jiang; Chaopin Li
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

7.  Ectopic Expression of Self-Antigen Drives Regulatory T Cell Development and Not Deletion of Autoimmune T Cells.

Authors:  Thomas Lee; Maran L Sprouse; Pinaki Banerjee; Maria Bettini; Matthew L Bettini
Journal:  J Immunol       Date:  2017-08-23       Impact factor: 5.422

8.  Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design.

Authors:  S A Thomson; S R Burrows; I S Misko; D J Moss; B E Coupar; R Khanna
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization.

Authors:  Kristin L Moffitt; Todd M Gierahn; Ying-jie Lu; Paulo Gouveia; Mark Alderson; Jessica Baker Flechtner; Darren E Higgins; Richard Malley
Journal:  Cell Host Microbe       Date:  2011-02-17       Impact factor: 21.023

10.  Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy.

Authors:  Kyle E Broaders; Joel A Cohen; Tristan T Beaudette; Eric M Bachelder; Jean M J Fréchet
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.